Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower

Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older. Competitors Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) are moving lower amid those headlines, however. Below, let's dig into how these stocks have fared on the charts lately. PCVX was last seen up 38.7% to trade at $111.98, and earlier notched a fresh all-time high of$119.27. The equity found re ...